Does Chronic Treatment with Oral Anticoagulants Ameliorate the Clinical Course of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Coronavirus Disease 2019 (COVID-19)?

Semin Thromb Hemost. 2021 Jun;47(4):338-340. doi: 10.1055/s-0040-1715091. Epub 2020 Sep 3.

Authors

Job Harenberg^{1

2}, Rupert Bauersachs³, Walter Ageno⁴

Affiliations

¹ Ruprecht Karls University, Heidelberg, Germany.
² Doasense GmbH, Heidelberg, Germany.
³ Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany.
⁴ Department of Medicine and Surgery, University of Insubria, Varese, Italy.

PMID: 32882715
DOI: 10.1055/s-0040-1715091

No abstract available

Publication types

Review

MeSH terms

Administration, Oral
Anticoagulants / administration & dosage
Anticoagulants / therapeutic use
Antithrombins / administration & dosage
Antithrombins / therapeutic use*
Atrial Fibrillation / epidemiology
Atrial Fibrillation / etiology
Brain Ischemia / epidemiology
Brain Ischemia / etiology
Brain Ischemia / prevention & control
COVID-19 / blood*
COVID-19 / complications
COVID-19 / mortality
Drug Monitoring
Drug Substitution
Factor Xa Inhibitors / administration & dosage
Factor Xa Inhibitors / therapeutic use
Humans
Inpatients
Prognosis
SARS-CoV-2*
Thrombophilia / drug therapy*
Thrombophilia / etiology
Venous Thromboembolism / epidemiology
Venous Thromboembolism / etiology
Venous Thromboembolism / prevention & control
Vitamin K / antagonists & inhibitors

Substances

Anticoagulants
Antithrombins
Factor Xa Inhibitors
Vitamin K